Olmetec Adverse Reactions

Common: Dizziness, bronchitis, cough, pharyngitis, rhinitis, abdominal pain, diarrhoea, dyspepsia, gastroenteritis, nausea, arthritis, back pain, skeletal pain, haematuria, urinary tract infection, chest pain, fatigue, influenza-like symptoms, peripheral oedema and pain.
Uncommon: Vertigo, angina pectoris, rash. Rare : hypotension.
Post-Launch Experience: In addition, as with other angiotensin II antagonists, headache has been observed. In very rare cases, hypersensitivity reactions (pruritus, urticaria, angioedema), peripheral oedema, vomiting, diarrhea, anaphylactic reaction, acute renal failure, myalgia and asthenic condition eg, asthenia, fatigue, lethargy, malaise have been reported.
Laboratory Parameters: In placebo-controlled monotherapy studies the incidence was somewhat higher on olmesartan medoxomil compared with placebo for hypertriglyceridaemia (2.0% versus 1.1%) and for raised creatine phosphokinase (1.3% vs 0.7%).
Laboratory adverse events reported across all clinical trials with olmesartan medoxomil (including trials without a placebo control), irrespective of causality or incidence relative to placebo, included: Metabolic and Nutritional Disorders: Common: Increased creatine phosphokinase, hypertriglyceridaemia, hyperuricaemia. Rare: Hyperkalaemia.
Liver and Biliary Disorders: Common: Liver enzyme elevations.